2024
The Promise and Perils of Diversity Action Plans for Clinical Trials
Varma T, Bierer B, Hantel A. The Promise and Perils of Diversity Action Plans for Clinical Trials. JAMA 2024, 332 PMID: 39302826, DOI: 10.1001/jama.2024.18225.Peer-Reviewed Original Research
2023
Data transparency and demographic representation in approval packages of FDA-approved oncology drugs from 2012-2021.
Liu J, Jayaram G, Varma T, Sammut S, Guerra C, Miller J. Data transparency and demographic representation in approval packages of FDA-approved oncology drugs from 2012-2021. Journal Of Clinical Oncology 2023, 41: 1594-1594. DOI: 10.1200/jco.2023.41.16_suppl.1594.Peer-Reviewed Original ResearchPivotal trialsDrug approval packagesClinical trialsApproval packagesNovel cancer therapeuticsDemographic dataCancer therapeuticsUS cancer populationUS Cancer StatisticsCross-sectional studyOncology clinical trialsPercentage of participantsClinical trial infrastructurePercentage of trialsCancer populationProportion of trialsCancer statisticsDrug AdministrationOncology drugsTrial infrastructureCancer typesData reportingU.S. FoodOlder adultsTrials